Genomic and post-genomic analyses of human prion diseases

Genome Medicine

Volumn 1, Issue 6, 2009, Pages

  Pocchiari, Maurizio ^a,b   Poleggi, Anna ^a   Principe, Serena ^a   Graziano, Silvia ^a,b   Cardone, Franco ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b CEA   (France)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E4; ASPARAGINE; ASPARTIC ACID; GENE PRODUCT; LEUCINE; METHIONINE; PRION PROTEIN; PROLINE; PROTEIN HECTD2; PROTEIN S100B; PROTEIN SPRN; PROTEIN STMN2; RETINOIC ACID RECEPTOR BETA; SYNAPTOPHYSIN; SYNAPTOSOMAL ASSOCIATED PROTEIN 25; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; BRAIN DAMAGE; CEREBROSPINAL FLUID ANALYSIS; CREUTZFELDT JAKOB DISEASE; DISEASE MARKER; GENE EXPRESSION; GENE IDENTIFICATION; GENE INSERTION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENOMICS; HOMOZYGOSITY; HUMAN; METABOLOMICS; MUTATIONAL ANALYSIS; NONHUMAN; PATHOGENESIS; PHENOTYPE; POINT MUTATION; PRION DISEASE; PRIORITY JOURNAL; PROTEOMICS; REVIEW; RISK FACTOR; SCRAPIE AGENT; SINGLE NUCLEOTIDE POLYMORPHISM; UPREGULATION; VARIANT CREUTZFELDT JAKOB DISEASE;

EID: 70350188098     PISSN: None     EISSN: 1756994X     Source Type: Journal    
DOI: 10.1186/gm63     Document Type: Review

References (73)

1. Stewart LA, Rydzewska LH, Keogh GF, Knight RS: Systematic review of therapeutic interventions in human prion disease. Neurology 2008, 70:1272-1281.
2. Aguzzi A, Sigurdson C, Heikenwaelderw M: Molecular mechanisms of prion pathogenesis. Annu Rev Pathol 2008, 3:11-40
3. Caughey B, Lansbury PT: Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu Rev Neurosci 2003, 26:267-298.
4. Ladogana A, Puopolo M, Croes EA, Budka H, Jarius C, Collins S, Klug GM, Sutcliffe T, Giulivi A, Alperovitch A, Delasnerie-Laupretre N, Brandel J-P, Poser S, Kretzschmar H, Rietveld I, Mitrova E, de Pedro Cuesta J, Martinez-Martin P, Glatzel M, Aguzzi A, Knight R, Ward H, Pocchiari M, van Duijn CM, Will RG, Zerr I: Mortality from Creutzfeldt-Jakob disease and related disorders in Europe, Australia and Canada. Neurology 2005, 64:1586-1591.
5. Ladogana A, Puopolo M, Poleggi A, Almonti S, Mellina V, Equestre M, Pocchiari M: High incidence of genetic human transmissible spongiform encephalopathies in Italy. Neurology 2005, 64:1592-1597.
6. Capellari S, Parchi P, Cortelli P, Avoni P, Casadei GP, Bini C, Baruzzi A, Lugaresi E, Pocchiari M, Gambetti P, Montagna P: Sporadic fatal insomnia in a fatal familial insomnia pedigree. Neurology 2008, 70: 884-885.
7. Webb TEF, Pal S, Siddique D, Heaney DC, Linehan JM, Wadsworth JDF, Joiner S, Beck J, Wroe SJ, Stevenson V, Brandner S, Mead S, Collinge J: First report of Creutzfeldt-Jakob disease occurring in 2 siblings unexplained by PRNP mutation. J Neuropathol Exp Neurol 2008, 67:838-841.
8. Brown P, Gibbs CJ Jr, Rodgers-Johnson P, Asher DM, Sulima MP, Bacote A, Goldfarb LG, Gajdusek DC: Human spongiform encephalopathy: the National Institutes of Health series of 300 cases of experimentally transmitted disease. Ann Neurol 1994, 35:513-529.
9. Tateishi J, Kitamoto T, Hoque MZ, Furukawa H: Experimental transmission of Creutzfeldt-Jakob disease and related diseases to rodents. Neurology 1996, 46:532-537.
10. Bruce ME, Will RG, Ironside JW, McConnell I, Drummond D, Suttie A, McCardle L, Chree A, Hope J, Birkett C, Cousens S, Fraser H, Bostock CJ: Transmissions to mice indicate that 'new variant' CJD is caused by the BSE agent. Nature 1997, 389:498-501.
11. Baron T: Mouse models of prion disease transmission. Trends Mol Med 2002, 8:495-500.
12. Trevitt CR, Collinge J: A systematic review of prion therapeutics in experimental models. Brain 2006, 129:2241-2265.
13. Pocchiari M, Ladogana A, Graziano S, Puopolo M: Creutzfeldt-Jakob disease: hopes for therapy. Eur J Neurol 2008, 15:435-436.
14. Will RG, Ironside JW, Zeidler M, Cousens SN, Estibeiro K, Alperovitch A, Poser S, Pocchiari M, Hofman A, Smith PG: A new variant of Creutzfeldt-Jakob disease in the UK. Lancet 1996, 347:921-925.
15. Pocchiari M: Prevalence of variant CJD in the UK. BMJ 2009, 338: b435.
16. Brown P, Brandel J-P, Preese, M, Sato T: Iatrogenic Creutzfeldt-Jakob disease. The waning of an era. Neurology 2006, 67:389-393.
17. Turner ML, Ludlam CA: An update on the assessment and management of the risk of transmission of variant Creutzfeldt-Jakob disease by blood and plasma products. Br J Haematol 2009, 144:14-23.
18. Eaton L: Haemophilia patient had variant CJD agent in spleen. BMJ 2009, 338:b705.
19. Gambetti P, Kong Q, Zou W, Parchi P, Chen SG: Sporadic and familial CJD: classification and characterisation. Br Med Bull 2003, 66:213-239.
20. Barbanti P, Fabbrini G, Salvatore M, Petraroli R, Cardone F, Maras B, Equestre M, Macchi G, Lenzi GL, Pocchiari M: Polymorphism at codon 129 or codon 219 of PRNP and clinical heterogeneity in a previously unreported family with Gerstmann-Sträussler-Scheinker disease (PrP-P102L mutation). Neurology 1996, 47:734-741.
21. Webb TE, Poulter M, Beck J, Uphill J, Adamson G, Campbell T, Linehan J, Powell C, Brandner S, Pal S, Siddique D, Wadsworth JD, Joiner S, Alner K, Petersen C, Hampson S, Rhymes C, Treacy C, Storey E, Geschwind MD, Nemeth AH, Wroe S, Collinge J, Mead S: Phenotypic heterogeneity and genetic modification of P102L inherited prion disease in an international series. Brain 2008, 131:2632-2646.
22. Webb TE, Whittaker J, Collinge J, Mead S: Age of onset and death in inherited prion disease are heritable. Am J Med Genet B Neuropsychiatr Genet 2009, 150B:496-501.
23. Pocchiari M, Puopolo M, Croes EA, Budka H, Gelpi E, Collins S, Lewis V, Sutcliffe T, Giulivi A, Delasnerie-Laupretre N, Brandel J-P, Alperovitch A, Zerr I, Poser S, Kretzschmar HA, Ladogana A, Rietvald I, Mitrova E, Martinez-Martin P, de Pedro-Cuesta J, Glatzel M, Aguzzi A, Cooper S, Mackenzie J, van Duijn CM, Will RG: Predictors of survival in sporadic Creutzfeldt-Jakob disease and other human transmissible spongiform encephalopathies. Brain 2004, 127: 2348-2359.
24. van Duijn CM, Delasnerie-Lauprêtre N, Masullo C, Zerr I, de Silva R, Wientjens DP, Brandel JP, Weber T, Bonavita V, Zeidler M, Alpérovitch A, Poser S, Granieri E, Hofman A, Will RG: Casecontrol study of risk factors of Creutzfeldt-Jakob disease in Europe during 1993-95. European Union (EU) Collaborative Study Group of Creutzfeldt-Jakob disease (CJD). Lancet 1998, 351:1081-1085.
25. Ward HJ, Everington D, Cousens SN, Smith-Bathgate B, Gillies M, Murray K, Knight RS, Smith PG, Will RG: Risk factors for sporadic Creutzfeldt-Jakob disease. Ann Neurol 2008, 63:347-354.
26. Dickinson AG, Meikle VMH, Fraser H: Identification of a gene which controls the incubation period of some strains of scrapie agent in mice. J Comp Pathol 1968, 78:293-299.
27. Outram GW: The pathogenesis of scrapie in mice. In Slow Virus Diseases of Animals and Man. Edited by Kimberlin RH. Amsterdam: North-Holland Publishing Company; 1976:325-357.
28. Moreno CR, Lantier F, Lantier I, Sarradin P, Elsen JM: Detection of new quantitative trait Loci for susceptibility to transmissible spongiform encephalopathies in mice. Genetics 2003, 165:2085-2091.
29. Mead S, Poulter M, Uphill J, Beck J, Whitfield J, Webb TE, Campbell T, Adamson G, Deriziotis P, Tabrizi SJ, Hummerich H, Verzilli C, Alpers MP, Whittaker JC, Collinge J: Genetic risk factors for variant Creutzfeldt-Jakob disease: a genome-wide association study. Lancet Neurol 2009, 8:57-66.
30. Alpers MP: Review. The epidemiology of kuru: monitoring the epidemic from its peak to its end. Philos Trans R Soc Lond B Biol Sci 2008, 363:3707-3713.
31. Mead S, Mahal SP, Beck J, Campbell T, Farrall M, Fisher E, Collinge J: Sporadic - but not variant - Creutzfeldt-Jakob disease is associated with polymorphisms upstream of PRNP exon 1. Am J Hum Genet 2001, 69:1225-1235.
32. Vollmert C, Windl O, Xiang W, Rosenberger A, Zerr I, Wichmann HE, Bickeböller H, Illig T; KORA group, Kretzschmar HA: Significant association of a M129V independent polymorphism in the 5' UTR of the PRNP gene with sporadic Creutzfeldt-Jakob disease in a large German case-control study. J Med Genet 2006, 43:e53.
33. Rybner C, Hillion J, Sahraoui T, Lanotte M, Botti J: All-trans retinoic acid down-regulates prion protein expression independently of granulocyte maturation. Leukemia 2002, 16:940-948.
34. Kristiansen M, Messenger MJ, Klöhn PC, Brandner S, Wadsworth JD, Collinge J, Tabrizi SJ: Disease-related prion protein forms aggresomes in neuronal cells leading to caspase activation and apoptosis. J Biol Chem 2005, 280:38851-38861.
35. Beck JA, Campbell TA, Adamson G, Poulter M, Uphill JB, Molou E, Collinge J, Mead S: Association of a null allele of SPRN with variant Creutzfeldt-Jakob disease. J Med Genet 2008, 45:813-817.
36. Lloyd SE, Maytham EG, Pota H, Grizenkova J, Molou E, Uphill J, Hummerich H, Whitfield J, Alpers MP, Mead S, Collinge J: HECTD2 is associated with susceptibility to mouse and human prion disease. PLoS Genet 2009, 5:e1000383.
37. Premzl M, Sangiorgio L, Strumbo B, Marshall Graves JA, Simonic T, Gready JE: Shadoo, a new protein highly conserved from fish to mammals and with similarity to prion protein. Gene 2003, 314:89-
38. Watts JC, Drisaldi B, Ng V, Yang J, Strome B, Horne P, Sy MS, Yoong L, Young R, Mastrangelo P, Bergeron C, Fraser PE, Carlson GA, Mount HT, Schmitt-Ulms G, Westaway D: The CNS glycoprotein Shadoo has PrP (C)-like protective properties and displays reduced levels in prion infections. EMBO J 2007, 26:4038-4050.
39. Xiang W, Windl O, Westner IM, Neumann M, Zerr I, Lederer RM, Kretzschmar HA: Cerebral gene expression profiles in sporadic Creutzfeldt-Jakob disease. Ann Neurol 2005, 58:242-257.
40. Minghetti L, Pocchiari M: Cyclooxygenase-2, prostaglandin e(2), and microglial activation in prion diseases. Int Rev Neurobiol 2007, 82:265-275.
41. Kawashima T, Doh-ura K, Torisu M, Uchida Y, Furuta A, Iwaki T: Differential expression of metallothioneins in human prion diseases. Dement Geriatr Cogn Disord 2000, 11:251-262.
42. Ferrer I, Rivera R, Blanco R, Martí E: Expression of proteins linked to exocytosis and neurotransmission in patients with Creutzfeldt-Jakob disease. Neurobiol Dis 1999, 6:92-100.
43. Sanchez-Juan P, Green A, Ladogana A, Cuadrado-Corrales N, Sáanchez-Valle R, Mitrováa E, Stoeck K, Sklaviadis T, Kulczycki J, Hess K, Bodemer M, Slivarichová D, Saiz A, Calero M, Ingrosso L, Knight R, Janssens AC, van Duijn CM, Zerr I: CSF tests in the differential diagnosis of Creutzfeldt-Jakob disease. Neurology 2006, 67:637-643.
44. Pennington C, Chohan G, Mackenzie J, Andrews M, Will R, Knight R, Green A: The role of cerebrospinal fluid proteins as early diagnostic markers for sporadic Creutzfeldt-Jakob disease. Neurosci Lett 2009, 455:56-59.
45. Ladogana A, Sanchez-Juan P, Mitrová E, Green A, Cuadrado-Corrales N, Sánchez-Valle R, Koscova S, Aguzzi A, Sklaviadis T, Kulczycki J, Gawinecka J, Saiz A, Calero M, van Duijn CM, Pocchiari M, Knight R, Zerr I: Cerebrospinal fluid biomarkers in human genetic transmissible spongiform encephalopathies. J Neurol 2009. doi: 10.1007/s00415-009-5163-x.
46. Brechlin P, Jahn O, Steinacker P, Cepek L, Kratzin H, Lehnert S, Jesse S, Mollenhauer B, Kretzschmar HA, Wiltfang J, Otto M: Cerebrospinal fluid-optimized two-dimensional difference gel electrophoresis (2-D DIGE) facilitates the differential diagnosis of Creutzfeldt-Jakob disease. Proteomics 2008, 8:4357-4366.
47. Schmidt H, Otto M, Niedmann P, Cepek L, Schröter A, Kretzschmar HA, Poser S: CSF lactate dehydrogenase activity in patients with Creutzfeldt-Jakob disease exceeds that in other dementias. Dement Geriatr Cogn Disord 2004, 17:204-206.
48. Minghetti L, Greco A, Cardone F, Puopolo M, Ladogana A, Almonti S, Cunningham C, Perry VH, Pocchiari M, Levi G: Increased brain synthesis of prostaglandin E2 and F2-isoprostane in human and experimental transmissible spongiform encephalopathies. J Neuropathol Exp Neurol 2000, 59:866-871.
49. Minghetti L, Cardone F, Greco A, Puopolo M, Levi G, Green AJ, Knight R, Pocchiari M: Increased CSF levels of prostaglandin E(2) in variant Creutzfeldt-Jakob disease. Neurology 2002, 58:127-129.
50. Lekishvili T, Sassoon J, Thompsett AR, Green A, Ironside JW, Brown DR: BSE and vCJD cause disturbance to uric acid levels. Exp Neurol 2004, 190:233-244.
51. Giorgi A, Di Francesco L, Principe S, Mignogna G, Sennel L, Mancone C, Alonzi T, Sbriccoli M, De Pascalis A, Rappsilber J, Cardone F, Pocchiari M, Maras B, Schininá ME: Proteomic profiling of PrP27-30-enriched preparations extracted from the brain of hamsters with experimental scrapie. Proteomics in press.
52. Jang B, Kim E, Choi JK, Jin JK, Kim JI, Ishigami A, Maruyama N, Carp RI, Kim YS, Choi EK: Accumulation of citrullinated proteins by upregulated peptidylarginine deiminase 2 in brains of scrapie-infected mice: a possible role in pathogenesis. Am J Pathol 2008, 173:1129-1142.
53. Biasini E, Massignan T, Fioriti L, Rossi V, Dossena S, Salmona M, Forloni G, Bonetto V, Chiesa R: Analysis of the cerebellar proteome in a transgenic mouse model of inherited prion disease reveals preclinical alteration of calcineurin activity. Proteomics 2006, 6:2823-2834.
54. Miele G, Seeger H, Marino D, Eberhard R, Heikenwalder M, Stoeck K, Basagni M, Knight R, Green A, Chianini F, Wüthrich RP, Hock C, Zerr I, Aguzzi A: Urinary alpha1-antichymotrypsin: a biomarker of prion infection. PLoS ONE 2008, 3:e3870.
55. Guillaume E, Zimmermann C, Burkhard PR, Hochstrasser DF, Sanchez JC: A potential cerebrospinal fluid and plasmatic marker for the diagnosis of Creutzfeldt-Jakob disease. Proteomics 2003, 3:1495-1499.
56. Steinacker P, Mollenhauer B, Bibl M, Cepek L, Esselmann H, Brechlin P, Lewczuk P, Poser S, Kretzschmar HA, Wiltfang J, Trenkwalder C, Otto M: Heart fatty acid binding protein as a potential diagnostic marker for neurodegenerative diseases. Neurosci Lett 2004, 370:36-39.
57. Hesketh S, Sassoon J, Knight R, Brown DR: Elevated manganese levels in blood and CNS in human prion disease. Mol Cell Neurosci 2008, 37:590-598.
58. Cordery RJ, MacManus D, Godbolt A, Rossor MN, Waldman AD: Short TE quantitative proton magnetic resonance spectroscopy in variant Creutzfeldt-Jakob disease. Eur Radiol 2006, 16:1692-1698.
59. Sarac H, Hajnsek S, Basic S, Henigsberg N, Rados M, Simic G: Magnetic resonance spectroscopy and measurement of tau epitopes of autopsy proven sporadic Creutzfeldt-Jakob disease in a patient with non-specific initial EEG, MRI and negative 14-3-3 immunoblot. Coll Antropol 2008, 32(Suppl 1):199-204.
60. Waldman AD, Cordery RJ, MacManus DG, Godbolt A, Collinge J, Rossor MN: Regional brain metabolite abnormalities in inherited prion disease and asymptomatic gene carriers demonstrated in vivo by quantitative proton magnetic resonance spectroscopy. Neuroradiology 2006, 48:428-433.
61. Fagge TJ, Barclay GR, Stove GC, Stove G, Robinson MJ, Head MW, Ironside JW, Turner ML: Application of atomic dielectric resonance spectroscopy for the screening of blood samples from patients with clinical variant and sporadic CJD. J Transl Med 2007, 5:41.
62. Beekes M, Lasch P, Naumann D: Analytical applications of Fourier transform-infrared (FT-IR) spectroscopy in microbiology and prion research. Vet Microbiol 2007, 123:305-319.
63. Piubelli C, Fiorini M, Zanusso G, Milli A, Fasoli E, Monaco S., Righetti PG: Searching for markers of Creutzfeldt-Jakob disease in cerebrospinal fluid by two-dimensional mapping. Proteomics 2006, 6(Suppl 1):S256-261.
64. Arlt S, Kontush A, Zerr I, Buhmann C, Jacobi C, Schröter A, Poser S, Beisiegel U: Increased lipid peroxidation in cerebrospinal fluid and plasma from patients with Creutzfeldt-Jakob disease. Neurobiol Dis 2002, 10:150-156.
65. Zerr I, Helmhold M, Poser S, Armstrong VW, Weber T: Apolipoprotein E phenotype frequency and cerebrospinal fluid concentration are not associated with Creutzfeldt-Jakob disease. Arch Neurol 1996, 53:1233-1238.
66. Choe LH, Green A, Knight RS, Thompson EJ, Lee KH: Apolipoprotein E and other cerebrospinal fluid proteins differentiate ante mortem variant Creutzfeldt-Jakob disease from ante mortem sporadic Creutzfeldt-Jakob disease. Electrophoresis 2002, 23:2242-2246.
67. Völkel D, Zimmermann K, Zerr I, Lindner T, Bodemer M, Poser S, Schwarz HP: C-reactive protein and IL-6: new marker proteins for the diagnosis of CJD in plasma? Transfusion 2001, 41:1509-1514.
68. Sanchez JC, Guillaume E, Lescuyer P, Allard L, Carrette O, Scherl A, Burgess J, Corthals GL, Burkhard PR, Hochstrasser DF: Cystatin C as a potential cerebrospinal fluid marker for the diagnosis of Creutzfeldt-Jakob disease. Proteomics 2004, 4:2229-2233.
69. Cepek L, Brechlin P, Steinacker P, Mollenhauer B, Klingebiel E, Bibl M, Kretzschmar HA, Wiltfang J, Otto M: Proteomic analysis of the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Dement Geriatr Cogn Disord 2007, 23:22-28.
70. Sharief MK, Green A, Dick JP, Gawler J, Thompson EJ: Heightened intrathecal release of proinflammatory cytokines in Creutzfeldt-Jakob disease. Neurology 1999, 52:1289-1291.
71. Stoeck K, Bodemer M, Zerr I: Pro- and anti-inflammatory cytokines in the CSF of patients with Creutzfeldt-Jakob disease. J Neuroimmunol 2006, 172:175-181.
72. Awerbuch G, Peterson P, Sandyk R: Elevated cerebrospinal fluid lactic acid levels in Creutzfeldt-Jakob disease. Int J Neurosci 1988, 42:1-5.
73. Bleich S, Kropp S, Degner D, Zerr I, Pilz J, Gleiter CH, Otto M, Rüther E, Kretzschmar HA, Wiltfang J, Kornhuber J, Poser S: Creutzfeldt-Jakob disease and oxidative stress. Acta Neurol Scand 2000, 101:332-334.